2015 was an important year in dermatology, especially in the therapeutic area. New treatments are available for chronic urticaria, psoriasis and angiofibromas of the face in the tubrous sclerosis complex context. In dermato-oncology, treatments of advanced cases of basal cell carcinomas and metastatic melanomas have significally improved. Finally, methylisothiazolinone remains a major allergen, responsible for contact allergy epidemic and for which it is urgent to establish a limitation of its use at European level.
Key words
Chronic urticaria; psoriasis; angiofibromas; VRESS; methylisothiazolinone; vismodegib; melanoma targeted therapy